Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Second-generation systemic triazole antifungal

Updated · Methodology

Mechanism

Posaconazole is a strong CYP3A4 inhibitor and can markedly raise exposure to drugs that this enzyme metabolises (posaconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and in vitro data suggest that drugs that markedly inhibit this enzyme may raise domperidone plasma levels (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Domperidone is associated with QT prolongation. Epidemiological studies also link it to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, AEMPS). Some azoles have also been associated with QT prolongation, and cases of torsade de pointes have been reported in people taking posaconazole. However, posaconazole did not increase the mean heart-rate-corrected QT interval (QTc) in healthy volunteers (posaconazole SmPC, EMA, and posaconazole label, US Food and Drug Administration, FDA). The documents do not say how much posaconazole raises domperidone levels.

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely, and these reports included people with other risk factors, electrolyte disturbances or concomitant medicines (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Uncommon effects of posaconazole include long QT syndrome, ECG abnormalities, palpitations, slow heart rate, supraventricular extrasystoles and fast heart rate. Rare effects include torsade de pointes, ventricular tachycardia, cardiorespiratory arrest and sudden death (posaconazole SmPC, European Medicines Agency, EMA). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with strong CYP3A4 inhibitors regardless of their own effect on the QT interval and names posaconazole among the systemic azole antifungals (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US posaconazole label contraindicates CYP3A4 substrates that prolong the QT interval, and the European SmPC says not to give posaconazole with such drugs. According to its own SmPC, domperidone meets both criteria (posaconazole label, US Food and Drug Administration, FDA, and posaconazole SmPC, European Medicines Agency, EMA; domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances, bradycardia and heart disease such as congestive heart failure (AEMPS). Monitor potassium, magnesium and calcium and correct any disturbance before and during posaconazole treatment. Use posaconazole with caution in heart-rate-corrected QT (QTc) prolongation, cardiomyopathy, especially with heart failure, sinus bradycardia and symptomatic arrhythmias (posaconazole SmPC, EMA, and FDA label). No document says how long to wait after stopping posaconazole before starting domperidone. The SmPC gives only the mean half-life of posaconazole, 29 hours for the tablets and 35 hours for the oral suspension (posaconazole SmPC, EMA). If domperidone and posaconazole have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Posaconazole